Cormorant Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Cormorant Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-900,000	Closed	-$13.1M	–	78
2021 Q4	$13.1M	Sell	900,000 -600,000	-40%	-$9.09M	0.78%	37
2021 Q3	$27M	Sell	1,500,000 -500,000	-25%	-$8.02M	1.1%	30
2021 Q2	$35.1M	Hold	2,000,000	–	–	1.19%	27
2021 Q1	$50.4M	Buy	+2,000,000	New	+$39.1M	1.12%	22
2019 Q4	–	Sell	-250,000	Closed	-$270K	–	69
2019 Q3	$270K	Hold	250,000	–	–	0.02%	73
2019 Q2	$548K	Sell	250,000 -170,555	-41%	-$930K	0.03%	69
2019 Q1	$2.52M	Sell	420,555 -57,500	-12%	-$381K	0.17%	60
2018 Q4	$3.53M	Sell	478,055 -21,945	-4%	-$226K	0.29%	56
2018 Q3	$7.26M	Sell	500,000 -25,538	-5%	-$438K	0.47%	44
2018 Q2	$10.5M	Hold	525,538	–	–	0.78%	39
2018 Q1	$9.21M	Sell	525,538 -24,462	-4%	-$518K	0.69%	30
2017 Q4	$13.6M	Hold	550,000	–	–	1.42%	24
2017 Q3	$14.2M	Sell	550,000 -170,000	-24%	-$4.56M	2.51%	14
2017 Q2	$19.5M	Sell	720,000 -80,000	-10%	-$2.17M	3.24%	9
2017 Q1	$23.9M	Sell	800,000 -176,286	-18%	-$5.08M	3.46%	8
2016 Q4	$26.5M	Buy	976,286 +75,000	+8%	+$1.91M	3.57%	8
2016 Q3	$23.1M	Hold	901,286	–	–	2.55%	12
2016 Q2	$16.6M	Buy	901,286 +253,342	+39%	+$5.02M	2.36%	15
2016 Q1	$12.3M	Hold	647,944	–	–	1.85%	19
2015 Q4	$17.5M	Buy	+647,944	New	+$12.6M	2.09%	15

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Cormorant Asset Management's ACRS Position: Q1 2022 in Review

Cormorant Asset Management sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 900,000 shares — an estimated $13.1M sold.

Cormorant Asset Management first reported a position in ACRS in Q4 2015 and held it in 20 quarters. The position peaked at $50.4M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

Cormorant Asset Management reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
Cormorant Asset Management sold 900,000 Aclaris Therapeutics shares in Q1 2022, an estimated $13.1M.
Cormorant Asset Management first reported a position in Aclaris Therapeutics in Q4 2015 and held it in 20 quarters.
Cormorant Asset Management's Aclaris Therapeutics position peaked at $50.4M in Q1 2021.
109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Cormorant Asset Management's 13F filing for Q1 2022, filed 16 May 2022.